Citron Research Just Called This "Pandemic Relic" Stock a Hidden Artificial Intelligence (AI) Opportunity. Time to Buy?
Citron Research thinks there is a lucrative AI stock hiding in the telemedicine market.
When analyzing stocks, listening to interviews or reading reports conducted by equity research analysts on Wall Street can be helpful. Personally, I find augmenting my own research with the findings of industry experts pretty valuable, as it helps build a more inclusive, well-rounded view of a business.
One drawback from this approach, however, is that it can be easy to buy into someone else's opinion quickly -- essentially getting distracted enough to not ask any questions. Last week, Citron Research made a splash after it labeled Teladoc Health (NYSE: TDOC) a hidden artificial intelligence (AI) opportunity that is still viewed by many as a "pandemic relic."
Citron's narrative has rejuvenated enthusiasm around Teladoc, but does that make the stock a buy? Read on to find out what I think.
